DARIEN, Conn., Oct. 28, 2011 /PRNewswire/ -- Cytogel Pharma, LLC. is pleased to announce today the presentation at the American Society of Anesthesiologists of study results and completed analysis of a Phase I study of Cyt-1010. Cyt-1010 is a proprietary compound and a chemically stabilized analogue of endomorphin 1, a naturally occurring pain modulator. This trial was designed as a safety study in normal healthy volunteers with additional pharmacodynamic end points. At the doses tested (up to 0.15 mg/kg) Cyt-1010 was generally well tolerated, and no severe adverse events or evidence of respiratory depression were reported. The trial included additional tests to measure sensitivity to painful stimuli and statistically significant prolongation of the threshold time for cold pain sensation was recorded at a dose of 0.1 mg/kg. Cyt-1010 is being developed for the treatment of acute and chronic pain conditions, including neuropathic pain and post-operative pain.
About Cytogel Pharma
Cytogel Pharma, LLC. is a biopharmaceutical development company based in Darien, Connecticut, focused on developing promising early-stage programs that offer significant potential both as platform technologies and high value product candidates. The company's portfolio includes novel analgesic product candidates and broadly useful polymer and hydrogel drug delivery platform technologies. Cytogel will develop products from these platform technologies to the point of demonstrated value and then license these products to other larger companies for the full scientific and clinical development and subsequent commercialization. To learn more about Cytogel, please visit our website at www.cytogelpharma.com.
CONTACT: C. Dean Maglaris, 203-966-9867
SOURCE Cytogel Pharma, LLC.